Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
9,917 results
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI): Complete Statistical AnalysisIndependent statistical analysis of P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- P2Independent statistical analysis of PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- P2P+IYIndependent statistical analysis of An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- P3: Pacemaker Patient Profiling Study: Complete Statistical AnalysisIndependent statistical analysis of P3: Pacemaker Patient Profiling Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00294060).
- PA 03-103Independent statistical analysis of Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PA21Independent statistical analysis of Study of Phosphate Levels in Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824460).
- PACBACKIndependent statistical analysis of Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PACEIndependent statistical analysis of Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACE-RBBBIndependent statistical analysis of Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACERIndependent statistical analysis of Providing Adolescent Contraception in the Emergency Room: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02475980).
- PACIFIC-AMIIndependent statistical analysis of Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack: primary endpoint results, effect…
- Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…
- Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).
- Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).
- PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PACTIndependent statistical analysis of Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…
- PAHIndependent statistical analysis of Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03638908).
- PAI vs FNBIndependent statistical analysis of Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pain Control Following Sinus Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pain Control Following Sinus Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03783702).
- Pain Expectations in Subjects With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Pain Expectations in Subjects With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02155257).
- Pain in Traumatic Brain Injury – Basile, MD: Complete Statistical AnalysisIndependent statistical analysis of Pain in Traumatic Brain Injury - Basile, MD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01136486).
- Pain Management in Teeth With Reversible Pulpitis: Complete Statistical AnalysisIndependent statistical analysis of Pain Management in Teeth With Reversible Pulpitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT07114198).
- Pain, Inflammation and Opioid Craving: Complete Statistical AnalysisIndependent statistical analysis of Pain, Inflammation and Opioid Craving: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04190563).
- Painted Playgrounds: Aim 2: Assessments: Complete Statistical AnalysisIndependent statistical analysis of Painted Playgrounds: Aim 2: Assessments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03885518).
- PAIRSIndependent statistical analysis of Study of Aripiprazole to Treat Children and Adolescents With Autism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00619190).
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: Complete Statistical AnalysisIndependent statistical analysis of Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Palu-COVIDIndependent statistical analysis of Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Pamidronate to Treat Osteogenesis Imperfecta in Children: Complete Statistical AnalysisIndependent statistical analysis of Pamidronate to Treat Osteogenesis Imperfecta in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00005901).
- PAMMIndependent statistical analysis of Physiological Augmentation of Mindfulness Meditation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02754557).
- PANCAX-3Independent statistical analysis of Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02588339).
- Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…
- PANORAMA_3Independent statistical analysis of Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02654990).